These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 33869816)

  • 21. Enzalutamide: looking back at its preclinical discovery.
    Ha YS; Kim IY
    Expert Opin Drug Discov; 2014 Jul; 9(7):837-45. PubMed ID: 24820058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.
    Shiota M; Yokomizo A; Takeuchi A; Itsumi M; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Prostate; 2014 Jun; 74(9):959-69. PubMed ID: 24740858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
    Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
    Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists.
    Ivachtchenko AV; Ivanenkov YA; Mitkin OD; Vorobiev AA; Kuznetsova IV; Shevkun NA; Koryakova AG; Karapetian RN; Trifelenkov AS; Kravchenko DV; Veselov MS; Chufarova NV
    Eur J Med Chem; 2015 Jun; 99():51-66. PubMed ID: 26046313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
    Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
    Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.
    Poutiainen PK; Huhtala T; Jääskeläinen T; Petsalo A; Küblbeck J; Kaikkonen S; Palvimo JJ; Raunio H; Närvänen A; Peräkylä M; Juvonen RO; Honkakoski P; Laatikainen R; Pulkkinen JT
    Mol Cell Endocrinol; 2014 Apr; 387(1-2):8-18. PubMed ID: 24565895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
    Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S
    Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity.
    Xie XX; Li H; Wang J; Mao S; Xin MH; Lu SM; Mei QB; Zhang SQ
    Bioorg Med Chem; 2015 Oct; 23(19):6477-85. PubMed ID: 26321603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
    Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y
    Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and synthesis of indoline thiohydantoin derivatives based on enzalutamide as antiproliferative agents against prostate cancer.
    Zuo M; Xu X; Xie Z; Ge R; Zhang Z; Li Z; Bian J
    Eur J Med Chem; 2017 Jan; 125():1002-1022. PubMed ID: 27810589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.
    Kandil S; Westwell AD; McGuigan C
    Bioorg Med Chem Lett; 2016 Apr; 26(8):2000-4. PubMed ID: 26965862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3D-QSAR and scaffold hopping based designing of benzo[d]ox-azol-2(3H)-one and 2-oxazolo[4,5-b]pyridin-2(3H)-one derivatives as selective aldehyde dehydrogenase 1A1 inhibitors: Synthesis and biological evaluation.
    Verma H; Narendra G; Raju B; Kumar M; Jain SK; Tung GK; Singh PK; Silakari O
    Arch Pharm (Weinheim); 2022 Sep; 355(9):e2200108. PubMed ID: 35618489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lupeol, an androgen receptor inhibitor, enhances the chemosensitivity of prostate cancer stem cells to antiandrogen enzalutamide-based therapy.
    Khan MA; Singh D; Jameel M; Maurya SK; Singh S; Akhtar K; Siddique HR
    Toxicol Appl Pharmacol; 2023 Nov; 478():116699. PubMed ID: 37777120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis of Novel Pyridine Bearing Biologically Active Imidiazolyl, Pyrazolyl, Oxa/thiadiazolyl and Urea Derivatives as Promising Anticancer Agents.
    Hafez HN; El-Gazzar ABA
    Curr Org Synth; 2020; 17(1):55-64. PubMed ID: 32103718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery, synthesis and molecular substantiation of N-(benzo[d]thiazol-2-yl)-2-hydroxyquinoline-4-carboxamides as anticancer agents.
    Bindu B; Vijayalakshmi S; Manikandan A
    Bioorg Chem; 2019 Oct; 91():103171. PubMed ID: 31382059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer.
    Kandil SB; Kariuki BM; McGuigan C; Westwell AD
    Bioorg Med Chem Lett; 2021 Mar; 36():127817. PubMed ID: 33513386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
    Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
    Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics.
    Wangtrakuldee P; Adeniji AO; Zang T; Duan L; Khatri B; Twenter BM; Estrada MA; Higgins TF; Winkler JD; Penning TM
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105283. PubMed ID: 30641225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells.
    Hellsten R; Stiehm A; Palominos M; Persson M; Bjartell A
    Transl Oncol; 2022 Oct; 24():101495. PubMed ID: 35917644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.